Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
23andMe Holding Co. stock logo
ME
23andMe
$0.47
+1.3%
$0.52
$0.35
$2.21
$224.56M1.277.16 million shs1.73 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$15.44
+4.8%
$17.51
$12.95
$25.47
$1.40B0.81793,993 shs119,340 shs
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$54.99
$54.93
$14.91
$55.19
$1.34B0.03931,731 shsN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.37
-0.3%
$42.13
$24.69
$45.76
$1.59B0.6146,025 shs8,878 shs
Xencor, Inc. stock logo
XNCR
Xencor
$20.21
+5.1%
$22.10
$16.49
$28.96
$1.24B0.76683,361 shs177,086 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
23andMe Holding Co. stock logo
ME
23andMe
-1.73%-9.20%-5.90%-38.64%-75.45%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-4.54%-0.74%-11.64%-2.58%-18.12%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00%0.00%0.00%0.00%0.00%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
+0.66%+0.54%+0.81%-1.85%+67.97%
Xencor, Inc. stock logo
XNCR
Xencor
+1.10%+1.48%-10.68%-4.23%-28.51%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
23andMe Holding Co. stock logo
ME
23andMe
0.5273 of 5 stars
1.04.00.00.01.32.50.6
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.8157 of 5 stars
3.43.00.00.02.54.20.0
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.775 of 5 stars
1.03.00.00.01.22.51.9
Xencor, Inc. stock logo
XNCR
Xencor
4.1211 of 5 stars
4.41.00.03.92.60.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
23andMe Holding Co. stock logo
ME
23andMe
2.00
Hold$0.471.08% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.88
Moderate Buy$41.25167.16% Upside
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
2.00
Hold$43.001.49% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.89
Moderate Buy$36.0078.13% Upside

Current Analyst Ratings

Latest XNCR, SRRA, TARO, RCUS, and ME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
23andMe Holding Co. stock logo
ME
23andMe
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$0.85 ➝ $0.47
4/16/2024
Xencor, Inc. stock logo
XNCR
Xencor
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$56.00 ➝ $38.00
3/25/2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
2/28/2024
Xencor, Inc. stock logo
XNCR
Xencor
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$37.00 ➝ $24.00
2/28/2024
Xencor, Inc. stock logo
XNCR
Xencor
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$32.00
2/28/2024
Xencor, Inc. stock logo
XNCR
Xencor
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$38.00 ➝ $34.00
2/28/2024
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $34.00
2/22/2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00
1/30/2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $30.00
1/30/2024
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $42.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
23andMe Holding Co. stock logo
ME
23andMe
$299.49M0.75N/AN/A$1.55 per share0.30
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$117M12.00N/AN/A$6.17 per share2.50
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$300K4,476.00N/AN/A$6.16 per share8.93
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$572.95M2.78$1.76 per share24.12$46.05 per share0.92
Xencor, Inc. stock logo
XNCR
Xencor
$168.34M7.34N/AN/A$10.99 per share1.84

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
23andMe Holding Co. stock logo
ME
23andMe
-$311.66M-$1.11N/AN/A-210.48%-52.99%-39.32%5/23/2024 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$307M-$4.15N/AN/AN/A-262.39%-57.17%-25.80%5/8/2024 (Confirmed)
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$25.44M$1.2234.73N/A7.48%3.26%2.67%5/28/2024 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$126.09M-$2.10N/AN/AN/A-74.90%-18.67%-15.23%5/13/2024 (Estimated)

Latest XNCR, SRRA, TARO, RCUS, and ME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.97N/A+$0.97N/AN/AN/A  
2/27/2024Q4 2023
Xencor, Inc. stock logo
XNCR
Xencor
$0.36-$0.31-$0.67-$0.31$77.63 million$44.70 million      
2/21/2024Q4 2023
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.09-$1.08+$0.01-$1.08$28.30 million$31.00 million      
2/7/2024Q3 2024
23andMe Holding Co. stock logo
ME
23andMe
N/A-$0.17-$0.17$0.24$56.30 million$44.75 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
23andMe Holding Co. stock logo
ME
23andMe
N/A
2.15
2.04
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/A
4.52
4.52
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.02
21.27
21.27
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.60
3.03
Xencor, Inc. stock logo
XNCR
Xencor
0.02
7.36
7.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
23andMe Holding Co. stock logo
ME
23andMe
36.10%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
99.30%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
23andMe Holding Co. stock logo
ME
23andMe
27.55%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
13.80%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
44.10%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
13.80%
Xencor, Inc. stock logo
XNCR
Xencor
4.97%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
23andMe Holding Co. stock logo
ME
23andMe
769482.92 million349.87 millionNot Optionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
57790.95 million78.33 millionOptionable
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
10924.42 million13.65 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28061.12 million58.08 millionOptionable

XNCR, SRRA, TARO, RCUS, and ME Headlines

SourceHeadline
Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Mutual of America Capital Management LLCXencor, Inc. (NASDAQ:XNCR) Shares Acquired by Mutual of America Capital Management LLC
marketbeat.com - April 21 at 4:44 AM
Xencor (NASDAQ:XNCR) Price Target Lowered to $38.00 at BTIG ResearchXencor (NASDAQ:XNCR) Price Target Lowered to $38.00 at BTIG Research
americanbankingnews.com - April 17 at 3:34 AM
Xencor (NASDAQ:XNCR) Stock Price Down 4.5% Following Analyst DowngradeXencor (NASDAQ:XNCR) Stock Price Down 4.5% Following Analyst Downgrade
americanbankingnews.com - April 17 at 1:32 AM
Analyst Scoreboard: 6 Ratings For XencorAnalyst Scoreboard: 6 Ratings For Xencor
markets.businessinsider.com - April 16 at 4:34 PM
Xencor (NASDAQ:XNCR) Stock Price Down 4.5% After Analyst DowngradeXencor (NASDAQ:XNCR) Stock Price Down 4.5% After Analyst Downgrade
marketbeat.com - April 16 at 12:23 PM
Xencor (NASDAQ:XNCR) PT Lowered to $38.00Xencor (NASDAQ:XNCR) PT Lowered to $38.00
marketbeat.com - April 16 at 10:25 AM
Xencor names Bart Cornelissen as new CFOXencor names Bart Cornelissen as new CFO
uk.investing.com - April 11 at 3:17 PM
Xencor Appoints Bart Cornelissen As CFOXencor Appoints Bart Cornelissen As CFO
markets.businessinsider.com - April 10 at 8:44 AM
Xencor Names Bart Cornelissen Chief Financial OfficerXencor Names Bart Cornelissen Chief Financial Officer
marketwatch.com - April 9 at 1:06 PM
Xencor Appoints Bart Cornelissen as Chief Financial OfficerXencor Appoints Bart Cornelissen as Chief Financial Officer
finance.yahoo.com - April 9 at 1:06 PM
Xencor Appoints Bart Cornelissen as Chief Financial OfficerXencor Appoints Bart Cornelissen as Chief Financial Officer
businesswire.com - April 9 at 8:01 AM
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from AnalystsXencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - April 9 at 2:30 AM
Insider Selling: Xencor, Inc. (NASDAQ:XNCR) SVP Sells 3,892 Shares of StockInsider Selling: Xencor, Inc. (NASDAQ:XNCR) SVP Sells 3,892 Shares of Stock
insidertrades.com - March 17 at 8:19 AM
Insider Selling: Xencor, Inc. (NASDAQ:XNCR) CEO Sells 12,528 Shares of StockInsider Selling: Xencor, Inc. (NASDAQ:XNCR) CEO Sells 12,528 Shares of Stock
insidertrades.com - March 17 at 7:44 AM
XNCR Apr 2024 30.000 callXNCR Apr 2024 30.000 call
finance.yahoo.com - March 16 at 4:01 PM
Insider Selling: Xencor, Inc. (NASDAQ:XNCR) CFO Sells 849 Shares of StockInsider Selling: Xencor, Inc. (NASDAQ:XNCR) CFO Sells 849 Shares of Stock
insidertrades.com - March 13 at 7:20 AM
Death in Cancer Drug Trial Hinders Xencor’s SharesDeath in Cancer Drug Trial Hinders Xencor’s Shares
labusinessjournal.com - March 11 at 1:52 PM
XNCR May 2024 22.500 putXNCR May 2024 22.500 put
finance.yahoo.com - March 9 at 5:32 PM
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
finance.yahoo.com - March 7 at 6:40 PM
Xencor’s Strategic Focus and Pipeline Progress Affirm Buy RatingXencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating
markets.businessinsider.com - March 1 at 4:23 PM
Piper Sandler Downgrades Xencor (XNCR)Piper Sandler Downgrades Xencor (XNCR)
msn.com - March 1 at 12:34 AM
Xencor Inc XNCRXencor Inc XNCR
morningstar.com - February 29 at 7:33 PM
Xencor Full Year 2023 Earnings: Misses ExpectationsXencor Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - February 29 at 9:31 AM
Xencor Q4 2023 Earnings PreviewXencor Q4 2023 Earnings Preview
seekingalpha.com - February 28 at 7:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

23andMe logo

23andMe

NASDAQ:ME
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
Arcus Biosciences logo

Arcus Biosciences

NYSE:RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Sierra Oncology logo

Sierra Oncology

NASDAQ:SRRA
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Taro Pharmaceutical Industries logo

Taro Pharmaceutical Industries

NYSE:TARO
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Xencor logo

Xencor

NASDAQ:XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.